Press Release History - 2011

  • 23 Dec 2011
    ThromboGenics Submits Biologics License
  • 23 Dec 2011
    ThromboGenics Submits Biologics License Application for Ocriplasmin to the U.S. FDA
  • 16 Dec 2011
    ThromboGenics and BioInvent Complete Enrollment of Phase IIb Trial with TB-402 ahead of schedule
  • 24 Nov 2011
    ThromboGenics Appoints Thomas Clay as New Board Member
  • 3 Nov 2011
    ThromboGenics NV – Business Update
  • 20 Oct 2011
    ThromboGenics Announces Dr Julia Haller to Present Ocriplasmin Phase III Responder Analysis at Opening Session of AAO (American Academy of Ophthalmology) Retina Subspecialty Day
  • 19 Oct 2011
    ThromboGenics Announces EMA Acceptance for Review of Marketing Authorisation Application for Ocriplasmin
  • 24 Aug 2011
    ThromboGenics NV – Business Update
  • 22 Aug 2011
    ThromboGenics Announces New Phase III Ocriplasmin Data Presented at the 2011 Annual Meeting of the American Society of Retina Specialists (ASRS)
  • 9 Aug 2011
    ThromboGenics on Track to File Ocriplasmin by End of 2011
  • 7 Jun 2011
    ThromboGenics to Present at the Jefferies 2011 Global Life Sciences Conference in New York
  • 16 May 2011
    ThromboGenics and BioInvent Announce the Start of New Study of Novel Antibody Anti-Cancer Agent TB-403 (Anti-PlGF) by Partner Roche
  • 12 May 2011
    ThromboGenics NV – Business Update
  • 27 Apr 2011
    ThromboGenics and BioInvent Have Dosed the First Patient in Phase IIb Trial of TB-402 (Anti-Factor VIII) for Venous Thromboembolism (VTE) Prophylaxis
  • 1 Apr 2011
    Thrombogenics increases share capital through warrant exercises
  • 10 Mar 2011
    ThromboGenics Announces Business Update and 2010 Full-Year Results
  • 11 Feb 2011
    Positive TB-402 (Anti-Factor VIII Antibody) Phase II Data Published in Journal of Thrombosis and Haemostasis
  • 4 Feb 2011
    Clot-Busting Drug THR-100 (Staphylokinase) Enters Phase III Clinical Trials in India
  • 20 Jan 2011
    THROMBOGENICS PRESENTS POSITIVE POOLED RESULTS FROM THE MIVI-TRUST PHASE III PROGRAM